General Information
Version
6.7
Revision date
2024-07-02
Product name
Alpha Integrin-Mediated Cell Adhesion Array Kit
REACH No
This
1.2.1 Relevant identified uses
Biochemical research/analysis
Emergency telephone
+(44)-870-8200418, +(353)-19014670, 001-803-017-9114
Icons in SDS
Company Information
company name
Merck KGaA
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H225, H319
Hazard statements
Code
Statements
H225
Highly Flammable liquid and vapour
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Flammable liquids, (Category 2) H225 Highly flammable liquid and vapor Eye irritation, (Category 2) H319: Causes serious eye irritation.
2.2 Label elements
Labelling
Signal word
Danger Danger
Hazard statements
H225 Highly flammable liquid and vapor. H319 Causes serious eye irritation. Reduced Labeling (<= 125 ml) none
Precautionary statements
P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. P233 Keep container tightly closed. P240 Ground and bond container and receiving equipment. P241 Use explosion-proof electrical/ ventilating/ lighting/ equipment. P242 Use non-sparking tools. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. none
Supplemental label elements
none none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
